<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7016805/results/search/disease/results.xml">
  <result pre="(N.A.B.) †These authors contributed equally to this work. ‡Current address:" exact="Chronic" post="Infectious and Inflammatory Diseases Research, School of Health and"/>
  <result pre="†These authors contributed equally to this work. ‡Current address: Chronic" exact="Infectious" post="and Inflammatory Diseases Research, School of Health and Biomedical"/>
  <result pre="contributed equally to this work. ‡Current address: Chronic Infectious and" exact="Inflammatory" post="Diseases Research, School of Health and Biomedical Sciences, RMIT"/>
  <result pre="equally to this work. ‡Current address: Chronic Infectious and Inflammatory" exact="Diseases" post="Research, School of Health and Biomedical Sciences, RMIT University,"/>
  <result pre="of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract" exact="Viral disease" post="is one of the greatest burdens for human health"/>
  <result pre="the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Viral" exact="disease" post="is one of the greatest burdens for human health"/>
  <result pre="is to develop antivirals targeting host cellular co-factors critical to" exact="viral" post="replication, such as DEAD-box helicase 3 X-linked (DDX3X), which"/>
  <result pre="co-factors critical to viral replication, such as DEAD-box helicase 3" exact="X-linked" post="(DDX3X), which plays key roles in RNA metabolism and"/>
  <result pre="and the antiviral response. Here, we use biochemical/biophysical approaches and" exact="infectious" post="assays to show for the first time that the"/>
  <result pre="that RK-33 is efficacious at low micromolar concentrations in limiting" exact="infection" post="by human parainfluenza virus type 3 (hPIV-3), respiratory syncytial"/>
  <result pre="low micromolar concentrations in limiting infection by human parainfluenza virus" exact="type 3" post="(hPIV-3), respiratory syncytial virus (RSV), dengue virus (DENV), Zika"/>
  <result pre="in limiting infection by human parainfluenza virus type 3 (hPIV-3)," exact="respiratory" post="syncytial virus (RSV), dengue virus (DENV), Zika virus (ZIKV)"/>
  <result pre="agent that blocks DDX3X’s catalytic activities in vitro and limits" exact="viral" post="replication in cells. DDX3X DEAD-box helicase RK-33 viral infection"/>
  <result pre="and limits viral replication in cells. DDX3X DEAD-box helicase RK-33" exact="viral infection" post="small molecule inhibitor 1. Introduction Viral infections pose a"/>
  <result pre="limits viral replication in cells. DDX3X DEAD-box helicase RK-33 viral" exact="infection" post="small molecule inhibitor 1. Introduction Viral infections pose a"/>
  <result pre="DEAD-box helicase RK-33 viral infection small molecule inhibitor 1. Introduction" exact="Viral" post="infections pose a risk to human health worldwide, with"/>
  <result pre="helicase RK-33 viral infection small molecule inhibitor 1. Introduction Viral" exact="infections" post="pose a risk to human health worldwide, with an"/>
  <result pre="few antivirals in use typically function by targeting a specific" exact="viral" post="protein critical to viral replication, and hence are only"/>
  <result pre="typically function by targeting a specific viral protein critical to" exact="viral" post="replication, and hence are only effective against a single"/>
  <result pre="strategy is to instead target host cellular cofactors critical to" exact="viral" post="replication. DEAD-box helicase 3 X-linked (DDX3X) is a cellular"/>
  <result pre="host cellular cofactors critical to viral replication. DEAD-box helicase 3" exact="X-linked" post="(DDX3X) is a cellular adenosine 5′-triphosphate (ATP)-dependent RNA helicase"/>
  <result pre="medical significance; it is required for the replication of human" exact="immunodeficiency" post="virus type 1 (HIV-1) [5,6], and flaviviruses such as"/>
  <result pre="it is required for the replication of human immunodeficiency virus" exact="type 1" post="(HIV-1) [5,6], and flaviviruses such as dengue virus (DENV)"/>
  <result pre="(HIV-1) [5,6], and flaviviruses such as dengue virus (DENV) and" exact="hepatitis" post="C (HCV) [7,8]. Accordingly, DDX3X is an attractive host"/>
  <result pre="site (Wnt) signaling [11,14], reduce mitochondrial translation [15], and reduce" exact="tumor" post="proliferation/growth in xenograft mouse models of Ewing sarcoma, lung"/>
  <result pre="[15], and reduce tumor proliferation/growth in xenograft mouse models of" exact="Ewing sarcoma," post="lung cancer and prostate cancer, with or without parallel"/>
  <result pre="reduce tumor proliferation/growth in xenograft mouse models of Ewing sarcoma," exact="lung cancer" post="and prostate cancer, with or without parallel radiation dosing"/>
  <result pre="tumor proliferation/growth in xenograft mouse models of Ewing sarcoma, lung" exact="cancer" post="and prostate cancer, with or without parallel radiation dosing"/>
  <result pre="in xenograft mouse models of Ewing sarcoma, lung cancer and" exact="prostate cancer," post="with or without parallel radiation dosing [11,13,14,15,16]. RK-33 is"/>
  <result pre="properties [19,20,21,22,23], we decided to test RK-33′s ability to inhibit" exact="infection" post="by viruses belonging to the Paramyxoviridae and Flaviviridae families."/>
  <result pre="in vitro ATPase and RNA unwinding assays. Importantly, using cell-based" exact="infectious" post="assays, we establish for the first time that RK-33"/>
  <result pre="RK-33 has antiviral activity against not only human parainfluenza virus" exact="type 3" post="(hPIV-3) and respiratory syncytial virus (RSV), but also several"/>
  <result pre="against not only human parainfluenza virus type 3 (hPIV-3) and" exact="respiratory" post="syncytial virus (RSV), but also several flaviviruses including DENV"/>
  <result pre="BioScience (Irvine, CA, USA). For in vitro experiments and cell-based" exact="infectious" post="assays, an RK-33 stock was made up to 50"/>
  <result pre="up to 50 mM in 100% dimethyl sulfoxide (DMSO). 2.2." exact="Protein" post="Expression and Purification Sequences encoding an N-terminal hexa-histidine (6His)"/>
  <result pre="500 mM NaCl, 20% (v/v) glycerol, and 0.5 mM TCEP." exact="Protein" post="fractions containing DDX3X were pooled and protein purity determined"/>
  <result pre="Coulter, Brea, CA, USA) at a temperature of 20 °C." exact="Protein" post="was diluted in 20 mM Tris, pH 8.0, 150"/>
  <result pre="cP at 20 °C), as well as estimates of the" exact="partial" post="specific volume (0.7247 mL/g for DDX3X at 20 °C), were"/>
  <result pre="cells) in a humidified incubator supplemented with 5% CO2 [29]." exact="Viral" post="stocks of DENV-2 (New Guinea C; M29095) were propagated"/>
  <result pre="cells at 80% confluency were infected at a multiplicity of" exact="infection" post="(MOI) of 0.1. At 48 h, when &amp;gt;70% of"/>
  <result pre="associated sample for RSV) was harvested as the virus stock." exact="Viral" post="titre was subsequently determined by plaque assay (see below)."/>
  <result pre="titre was subsequently determined by plaque assay (see below). 2.8." exact="Viral Infection" post="and RK-33 Treatment Vero cells were infected with DENV-2,"/>
  <result pre="was subsequently determined by plaque assay (see below). 2.8. Viral" exact="Infection" post="and RK-33 Treatment Vero cells were infected with DENV-2,"/>
  <result pre="vehicle DMSO. Culture medium was collected 22 h later and" exact="viral" post="titres determined by plaque assay or RT-qPCR. 2.9. Plaque"/>
  <result pre="removed by rinsing the cells with tap water, and the" exact="viral" post="plaques were counted visually. Dose-response curves were plotted from"/>
  <result pre="Polymerase Chain Reaction (qRT-PCR) qRT-PCR to estimate the number of" exact="viral" post="genomes was performed as previously for RSV [31], ZIKV"/>
  <result pre="primers: 5′-CCATCTGTTGGACCAGGGAT-3′ and 5′-TGATTGCAGTCCCTCTGTGT-3′. Dose-response curves were plotted from the" exact="viral" post="RNA copies versus the logarithmic value of the concentrations"/>
  <result pre="MO, USA). Cells were treated the same as for the" exact="infection" post="assay with increasing concentrations of RK-33, and XTT added"/>
  <result pre="activities, and test its ability to inhibit a range of" exact="viral" post="infections. 3.1. RK-33 Binds Directly to the Active Site"/>
  <result pre="hydrolysis and RNA-unwinding [6]. At 290 nm and in the" exact="absence of" post="RK-33, both DDX3X (Figure 1C, black) and DDX3X K230E"/>
  <result pre="absence or presence of increasing concentrations of RK-33. In the" exact="absence of" post="RK-33, DDX3X (Figure 2B) but not the DDX3X K230E"/>
  <result pre="for its anticancer properties, we tested its ability to limit" exact="infection" post="by key members of the Paramyxoviridae (RSV and hPIV-3)"/>
  <result pre="with comparable EC50 values (Figure 4, Table 1). Importantly, the" exact="viral" post="inhibitory effects of RK-33 were not due to cytotoxic"/>
  <result pre="Vero cell numbers/viability (Supplementary Figure S1). 4. Discussion Even though" exact="viral" post="infections pose a significant threat to human health, antivirals"/>
  <result pre="cell numbers/viability (Supplementary Figure S1). 4. Discussion Even though viral" exact="infections" post="pose a significant threat to human health, antivirals to"/>
  <result pre="is to develop antivirals targeting host cell co-factors critical to" exact="viral" post="replication. DDX3X is a prime host target for multiple"/>
  <result pre="required for replication of HIV-1 [5,6] and flaviviruses such as" exact="Japanese encephalitis" post="virus (JEV) [36] and HCV [7,8]. RK-33 is a"/>
  <result pre="for replication of HIV-1 [5,6] and flaviviruses such as Japanese" exact="encephalitis" post="virus (JEV) [36] and HCV [7,8]. RK-33 is a"/>
  <result pre="[11] reported inhibition of helicase activity of yeast Ded1p at" exact="lower" post="(nM) RK-33 concentrations. The basis of this difference in"/>
  <result pre="of compounds against the same enzyme from a range of" exact="bacterial" post="species [38]. REN analogues that modulate the helicase activity"/>
  <result pre="[38]. REN analogues that modulate the helicase activity of target" exact="viral" post="or host helicases have been shown to have antiviral"/>
  <result pre="against HIV-1 [21], HCV [22], JEV [22], WNV [22,23] and" exact="hepatitis" post="B [19,20]. Consistent with the antiviral properties of REN"/>
  <result pre="properties of REN derivatives and of agents targeting DDX3X, our" exact="virus infection" post="studies reveal here for the first time that the"/>
  <result pre="of REN derivatives and of agents targeting DDX3X, our virus" exact="infection" post="studies reveal here for the first time that the"/>
  <result pre="Interdiscip. Rev. RNA2013436938510.1002/wrna.116523606618 5.IshaqM.HuJ.WuX.FuQ.YangY.LiuQ.GuoD.Knockdown of cellular RNA helicase DDX3 by" exact="short" post="hairpin RNAs suppresses HIV-1 viral replication without inducing apoptosisMol."/>
  <result pre="cellular RNA helicase DDX3 by short hairpin RNAs suppresses HIV-1" exact="viral" post="replication without inducing apoptosisMol. Biotechnol.20083923123810.1007/s12033-008-9040-018259889 6.YedavalliV.S.NeuveutC.ChiY.H.KleimanL.JeangK.T.Requirement of DDX3 DEAD"/>
  <result pre="Rev-RRE export functionCell200411938139210.1016/j.cell.2004.09.02915507209 7.AriumiY.KurokiM.AbeK.DansakoH.IkedaM.WakitaT.KatoN.DDX3 DEAD-box RNA helicase is required for" exact="hepatitis" post="C virus RNA replicationJ. Virol.200781139221392610.1128/JVI.01517-0717855521 8.RandallG.PanisM.CooperJ.D.TellinghuisenT.L.SukhodoletsK.E.PfefferS.LandthalerM.LandgrafP.KanS.LindenbachB.D.et al.Cellular cofactors affecting"/>
  <result pre="hepatitis C virus RNA replicationJ. Virol.200781139221392610.1128/JVI.01517-0717855521 8.RandallG.PanisM.CooperJ.D.TellinghuisenT.L.SukhodoletsK.E.PfefferS.LandthalerM.LandgrafP.KanS.LindenbachB.D.et al.Cellular cofactors affecting" exact="hepatitis" post="C virus infection and replicationProc. Natl. Acad. Sci. USA2007104128841288910.1073/pnas.070489410417616579"/>
  <result pre="virus RNA replicationJ. Virol.200781139221392610.1128/JVI.01517-0717855521 8.RandallG.PanisM.CooperJ.D.TellinghuisenT.L.SukhodoletsK.E.PfefferS.LandthalerM.LandgrafP.KanS.LindenbachB.D.et al.Cellular cofactors affecting hepatitis C" exact="virus infection" post="and replicationProc. Natl. Acad. Sci. USA2007104128841288910.1073/pnas.070489410417616579 9.KondaskarA.KondaskarS.KumarR.FishbeinJ.C.MuvarakN.LapidusR.G.SadowskaM.EdelmanM.J.BolG.M.VesunaF.et al.Novel, broad"/>
  <result pre="RNA replicationJ. Virol.200781139221392610.1128/JVI.01517-0717855521 8.RandallG.PanisM.CooperJ.D.TellinghuisenT.L.SukhodoletsK.E.PfefferS.LandthalerM.LandgrafP.KanS.LindenbachB.D.et al.Cellular cofactors affecting hepatitis C virus" exact="infection" post="and replicationProc. Natl. Acad. Sci. USA2007104128841288910.1073/pnas.070489410417616579 9.KondaskarA.KondaskarS.KumarR.FishbeinJ.C.MuvarakN.LapidusR.G.SadowskaM.EdelmanM.J.BolG.M.VesunaF.et al.Novel, broad"/>
  <result pre="Lett.2008104681468410.1021/ol802017618816128 11.BolG.M.VesunaF.XieM.ZengJ.AzizK.GandhiN.LevineA.IrvingA.KorzD.TantravediS.et al.Targeting DDX3 with a small molecule inhibitor for" exact="lung cancer" post="therapyEMBO Mol. Med.2015764866910.15252/emmm.20140436825820276 12.AmemiyaY.AzmiP.SethA.Autoubiquitination of BCA2 RING E3 ligase"/>
  <result pre="11.BolG.M.VesunaF.XieM.ZengJ.AzizK.GandhiN.LevineA.IrvingA.KorzD.TantravediS.et al.Targeting DDX3 with a small molecule inhibitor for lung" exact="cancer" post="therapyEMBO Mol. Med.2015764866910.15252/emmm.20140436825820276 12.AmemiyaY.AzmiP.SethA.Autoubiquitination of BCA2 RING E3 ligase"/>
  <result pre="E3 ligase regulates its own stability and affects cell migrationMol." exact="Cancer" post="Res. MCR200861385139610.1158/1541-7786.MCR-08-009418819927 13.XieM.VesunaF.TantravediS.BolG.M.Heerma Van VossM.R.NugentK.MalekR.GabrielsonK.Van DiestP.J.TranP.T.et al.RK-33 radiosensitizes prostate"/>
  <result pre="migrationMol. Cancer Res. MCR200861385139610.1158/1541-7786.MCR-08-009418819927 13.XieM.VesunaF.TantravediS.BolG.M.Heerma Van VossM.R.NugentK.MalekR.GabrielsonK.Van DiestP.J.TranP.T.et al.RK-33 radiosensitizes" exact="prostate cancer" post="cells by blocking the RNA helicase DDX3Cancer Res.2016766340635010.1158/0008-5472.CAN-16-044027634756 14.Heerma"/>
  <result pre="Cancer Res. MCR200861385139610.1158/1541-7786.MCR-08-009418819927 13.XieM.VesunaF.TantravediS.BolG.M.Heerma Van VossM.R.NugentK.MalekR.GabrielsonK.Van DiestP.J.TranP.T.et al.RK-33 radiosensitizes prostate" exact="cancer" post="cells by blocking the RNA helicase DDX3Cancer Res.2016766340635010.1158/0008-5472.CAN-16-044027634756 14.Heerma"/>
  <result pre="mitochondrial translation by inhibiting DDX3: A novel radiosensitization strategy for" exact="cancer" post="treatmentOncogene201837637410.1038/onc.2017.30828869602 16.WilkyB.A.KimC.McCartyG.MontgomeryE.A.KammersK.DeVineL.R.ColeR.N.RamanV.LoebD.M.RNA helicase DDX3: A novel therapeutic target in"/>
  <result pre="fight the West Nile virus infectionJ. Med. Chem.201910.1021/acs.jmedchem.8b01403 19.ChenH.M.SoodR.HosmaneR.S.An efficient," exact="short" post="synthesis and potent anti-hepatitis B viral activity of a"/>
  <result pre="Med. Chem.201910.1021/acs.jmedchem.8b01403 19.ChenH.M.SoodR.HosmaneR.S.An efficient, short synthesis and potent anti-hepatitis B" exact="viral" post="activity of a novel ring-expanded purine nucleoside analogue containing"/>
  <result pre="20.SoodR.K.BhadtiV.S.FattomA.I.NasoR.B.KorbaB.E.KernE.R.ChenH.M.HosmaneR.S.Novel ring-expanded nucleoside analogs exhibit potent and selective inhibition of" exact="hepatitis" post="B virus replication in cultured human hepatoblastoma cellsAntivir. Res.20025315916410.1016/S0166-3542(01)00204-211750942"/>
  <result pre="selective inhibition of hepatitis B virus replication in cultured human" exact="hepatoblastoma" post="cellsAntivir. Res.20025315916410.1016/S0166-3542(01)00204-211750942 21.YedavalliV.S.ZhangN.CaiH.ZhangP.StarostM.F.HosmaneR.S.JeangK.T.Ring expanded nucleoside analogues inhibit RNA helicase"/>
  <result pre="21.YedavalliV.S.ZhangN.CaiH.ZhangP.StarostM.F.HosmaneR.S.JeangK.T.Ring expanded nucleoside analogues inhibit RNA helicase and intracellular human" exact="immunodeficiency" post="virus type 1 replicationJ. Med. Chem.2008515043505110.1021/jm800332m18680273 22.ZhangN.ChenH.M.KochV.SchmitzH.LiaoC.L.BretnerM.BhadtiV.S.FattomA.I.NasoR.B.HosmaneR.S.et al.Ring-expanded (&quot;fat&quot;)"/>
  <result pre="nucleoside analogues inhibit RNA helicase and intracellular human immunodeficiency virus" exact="type 1" post="replicationJ. Med. Chem.2008515043505110.1021/jm800332m18680273 22.ZhangN.ChenH.M.KochV.SchmitzH.LiaoC.L.BretnerM.BhadtiV.S.FattomA.I.NasoR.B.HosmaneR.S.et al.Ring-expanded (&quot;fat&quot;) nucleoside and nucleotide"/>
  <result pre="against flaviviridae NTPases/helicases, including those of the West Nile virus," exact="hepatitis" post="C virus, and Japanese encephalitis virusJ. Med. Chem.2003464149416410.1021/jm030842j12954067 23.ZhangN.ChenH.M.KochV.SchmitzH.MinczukM.StepienP.FattomA.I.NasoR.B.KalicharranK.BorowskiP.et"/>
  <result pre="those of the West Nile virus, hepatitis C virus, and" exact="Japanese encephalitis" post="virusJ. Med. Chem.2003464149416410.1021/jm030842j12954067 23.ZhangN.ChenH.M.KochV.SchmitzH.MinczukM.StepienP.FattomA.I.NasoR.B.KalicharranK.BorowskiP.et al.Potent inhibition of NTPase/helicase of"/>
  <result pre="of the West Nile virus, hepatitis C virus, and Japanese" exact="encephalitis" post="virusJ. Med. Chem.2003464149416410.1021/jm030842j12954067 23.ZhangN.ChenH.M.KochV.SchmitzH.MinczukM.StepienP.FattomA.I.NasoR.B.KalicharranK.BorowskiP.et al.Potent inhibition of NTPase/helicase of"/>
  <result pre="dengue virus infectionJ. Infect. Dis.20142101780179110.1093/infdis/jiu31924903662 31.BajorekM.CalyL.TranK.C.MaertensG.N.TrippR.A.BacharachE.TengM.N.GhildyalR.JansD.A.The Thr205 phosphorylation site within" exact="respiratory" post="syncytial virus matrix (M) protein modulates M oligomerization and"/>
  <result pre="Chem. Soc.2003125148591486610.1021/ja036166s14640663 34.CalyL.LiH.M.BogoyevitchM.A.JansD.A.c-Jun N-terminal kinase activity is required for efficient" exact="respiratory" post="syncytial virus productionBiochem. Biophys. Res. Commun.2017483646810.1016/j.bbrc.2017.01.00528062184 35.YangS.N.Y.AtkinsonS.C.FraserJ.E.WangC.MaherB.RomanN.ForwoodJ.K.WagstaffK.M.BorgN.A.JansD.A.Novel flavivirus antiviral"/>
  <result pre="host nuclear transport importin alpha/beta1 heterodimerCells2019828110.3390/cells8030281 36.LiC.GeL.L.LiP.P.WangY.DaiJ.J.SunM.X.HuangL.ShenZ.Q.HuX.C.IshagH.et al.Cellular DDX3 regulates" exact="Japanese encephalitis" post="virus replication by interacting with viral un-translated regionsVirology2014449708110.1016/j.virol.2013.11.00824418539 37.SongH.JiX.The"/>
  <result pre="nuclear transport importin alpha/beta1 heterodimerCells2019828110.3390/cells8030281 36.LiC.GeL.L.LiP.P.WangY.DaiJ.J.SunM.X.HuangL.ShenZ.Q.HuX.C.IshagH.et al.Cellular DDX3 regulates Japanese" exact="encephalitis" post="virus replication by interacting with viral un-translated regionsVirology2014449708110.1016/j.virol.2013.11.00824418539 37.SongH.JiX.The"/>
  <result pre="al.Cellular DDX3 regulates Japanese encephalitis virus replication by interacting with" exact="viral" post="un-translated regionsVirology2014449708110.1016/j.virol.2013.11.00824418539 37.SongH.JiX.The mechanism of RNA duplex recognition and"/>
  <result pre="Lett.20081884284410.1016/j.bmcl.2007.11.02618054225 Figure 1 RK-33 directly binds to DEAD-box helicase 3" exact="X-linked" post="(DDX3X) residue K230. (A) Coomassie-stained SDS-PAGE of purified recombinant"/>
  <result pre="heat-denatured RNA. Figure 3 RK-33 is a broad-spectrum inhibitor of" exact="infectious" post="virus. Vero cells were infected with (A) dengue virus"/>
  <result pre="(B) Zika virus (ZIKV), (C) West Nile virus (WNV), (D)" exact="respiratory" post="syncytial virus (RSV) or (E) human parainfluenza virus type"/>
  <result pre="(D) respiratory syncytial virus (RSV) or (E) human parainfluenza virus" exact="type 3" post="(hPIV-3) at a multiplicity of infection (MOI) of 1"/>
  <result pre="human parainfluenza virus type 3 (hPIV-3) at a multiplicity of" exact="infection" post="(MOI) of 1 for 2 h, after which virus"/>
  <result pre="cell-associated samples (for RSV) were collected 22 h later, and" exact="viral" post="titres (expressed as plaque forming units (pfu) per mL)"/>
  <result pre="determined by plaque assay. Dose-response curves were plotted from the" exact="viral" post="titres (pfu) versus the logarithmic value of the concentrations"/>
  <result pre="cell-associated samples (for RSV) were collected 22 h later, and" exact="viral" post="RNA (vRNA) copies determined by qRT-PCR. Dose-response curves were"/>
 </snippets>
</snippetsTree>
